Clinical trials: Neoadjuvant Immunochemotherapy
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Esophageal Squamous Cell Carcinoma
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study is a prospective, multicenter, open-label, observational cohort study. The primary endpoint is pathological complete response (pCR), and the secondary endpoints include R0 resection rate, ctDNA clearance rate, major…
- Trial name
- ctDNA (NCT06103890)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Non-small Cell Lung Cancer (NSCLC)
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC.
- Trial name
- PROPHET (NCT06977074)
- Testing
- PD-1 inhibitor, Platinum Doublet
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
Squamous Cell Non-small Cell Lung Cancer
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell…
- Trial name
- neoSCORE Ⅱ (NCT05429463)
- Testing
- Sintilimab, Carboplatin, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288360
- Testing
- Camrelizumab, Paclitaxel-albumin, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Non-Small Cell Lung Cancer
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world.
- Trial name
- NeoR-World (NCT05974007)
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT07236320
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant Chemoradiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yongtao Han
Esophageal Squamous Cell Carcinoma
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
This is a prospective, multi-cohort, exploratory clinical study designed to evaluate the efficacy and safety of neoadjuvant adebrelimab combined with chemotherapy in patients with resectable locally advanced thoracic esophageal…
- Trial name
- NCT07452601
- Testing
- Adebrelimab plus nab-paclitaxel and cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe.
- Trial name
- NCT07822906
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of a modified neoadjuvant immunotherapy plus chemotherapy (one cycle of Tislelizumab monotherapy followed by four cycles of…
- Trial name
- TRACE (NCT06469060)
- Testing
- neoadjuvant anti-PD-1 with DOC chemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer (NSCLC)
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
The goal of this clinical trial is to compare the efficacy and safety of neoadjuvant Stereotactic Body Radiotherapy (SBRT) combined with immunochemotherapy versus neoadjuvant immunochemotherapy.
- Trial name
- SACTION2401 (NCT06598527)
- Testing
- Stereotactic body radiotherapy (SBRT), Tislelizumab, Chemotherapy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Yang Hong
Esophagogastric Junction Adenocarcinoma
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction…
- Trial name
- NCT05170503
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Esophageal Squamous Cell Carcinoma
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant…
- Trial name
- NCT06354140
- Testing
- Tegafur
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Deep Learning Model, Pathological Complete Response
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy
This study presents the development and validation of an artificial intelligence (AI) prediction system that utilizes pre-neoadjuvant immunotherapy plain scans and enhanced multimodal CT scans to extract deep learning features.
- Conditions
- Deep Learning Model, Pathological Complete Response, Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06285058
- Testing
- No interventions
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Lung Cancer
Neoadjuvant Immunochemotherapy for Lung Cancer
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
- Trial name
- NCT06023797
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Shanghai Zhongshan Hospital